TrialAmerican journal of clinical oncology2019

Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805).

Mark N Stein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.